Skip to content
DataLookout
Menu

NCT06670872

A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia

StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

clinical efficacy at the end of treatment
Timeframe: up to the end of treatment, up to 4 weeks(estimation)

Secondary (3)

Incidence Rate of Adverse Event
The microbiological clearance rate
The all cause mortality rate

Arms and interventions

Eravacycline combination therapy group

Eravacycline is administered intravenously at a dosage of 1mg/kg, once every 12 hours. The duration of intravenous infusion is approximately 60 minutes.The combined drugs include sulbactam or compound preparations containing sulbactam, polymyxin B, beta-lactam antibiotics, etc., used according to their instructions for use or clinical practice guidelines.

Drugs: Eravacycline combination therapy group

Sites

2 sites in 1 country